|
- Novartis | Cafepharma Message Boards | Pharma Sales, Device Sales, Lab . . .
Anonymous board for Novartis
- Novartis | Cafepharma
Novartis (NVS) has received FDA approval for Itvisma, a groundbreaking gene therapy for spinal muscular atrophy (SMA) Itvisma is the first therapy targeting the genetic basis of SMA with a single, fixed dose
- October 27 2025 - Novartis shares slip, Avidity soars after $12 billion . . .
Novartis shares slip, Avidity soars after $12 billion biotech dealNovartis boardInnovent, Lilly's mazdutide trumps Novo's semaglutide in head-to-head diabetes, weight loss studyEli Lilly board, Novo Nordisk boardMapLight goes public via $250M IPO to fund Cobenfy competitor
- Avidity Biosciences | Cafepharma
Shares of Novartis fell 1% on Monday following news of the company's plans to acquire U S biotech Avidity Biosciences for about $12 billion, marking the Swiss drugmaker's largest acquisition under CEO Vas Narasimhan
- Pluvicto | Cafepharma
Novartis’ radiopharmaceutical Pluvicto (lutetium Lu 177 vipivotide tetraxetan) met its primary endpoint in the Phase III PSMAfore trial, resulting in better radiographic progression-free survival in PSMA-positive patients with metastatic castration-resistant prostate cancer, the company announced Monday
- Medical Equipment Device Sales - Cafepharma
Anonymous discussion boards for medical equipment device companies
- radioligands | Cafepharma
Novartis has shared detailed data showing its radioligand therapy Pluvicto could slow the progression of certain hormone-sensitive prostate cancers ahead of a planned application with the FDA
- Xolair | Cafepharma
Xolair, a 20-year-old asthma drug sold by Roche (ROG S) and Novartis (NOVN S) significantly reduced allergic reactions in people with multiple severe food allergies in a late-stage trial, researchers reported on Sunday at a medical meeting
|
|
|